Sarah Tomassetti

Sarah E. Tomassetti, MD

Assistant Professor, Department of Medicine, Hematology/Oncology

Languages

English

Education

Fellowship

Hematology/Oncology, Harbor-UCLA Medical Center, 2016

Degrees

MD, University of Southern California (USC), Keck School of Medicine, 2009
BA, University of Colorado, Boulder, 2006

Residency

Internal Medicine, Los Angeles County (LAC) – USC, 2013

Contact Information

Scientific Interests

Dr. Sarah Tomassetti is a hematologist and oncologist who specializes in the treatment of hematologic malignancies with particular interest in the treatment of Hodgkin and Non-Hodgkin lymphomas.

Highlighted Publications

Chen R, Palmer J, Tomassetti S, Popplewell L, Alluin J, Chomchan P, Nademanee A, Sidiqi T, Tsai N, Chen L, Zuo F, Abary R, Cai J, Herrera AF, Rossi JJ, Rosen ST, Forman SJ, Kwak LQ, and Holmberg L. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. Journal of Hematologic Oncology. 2018;11:87.

Sarah Tomassetti and Alex F. Herrera. Update on the role of brentuximab vedotin in classical Hodgkin lymphoma. Therapeutic Advances in Hematology. 2018;9(9):261-272.

Sarah Tomassetti and Robert Chen. The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma. Therapeutic Advances in Hematology. 2019;10.

Merryman R, Carreau NA, Pail O, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair S, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Cohen JB, Troxel AB, Diefenbach C, and Armand P. Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy. Blood 2018; 132(suppl. 1): 1626.

Carreau NA, Pail O, Armand P, Merryman R, Advani RH, Spinner MA, Herrera AF, Chen R, Tomassetti S, Ramchandren R, Hamid M, Assouline S, Santiago R, Wagner- Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Liu Y, Nathan S, Karmali R, Burkart M, Torka P, David K, Wei C, Lansigan F, Emery L, Persky D, Smith S, Godfrey J, Chavez J, Xia Y, Troxel AB, and Diefenbach C. Checkpoint Blockade May Sensitize Non-Hodgkin Lymphoma to Subsequent Therapy. Blood 2018; 132(suppl. 1): 93.